Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
– Data from the Global, Multiple Ascending Dose Phase 1/2 DELIVER Clinical Trial Anticipated in…
– Data from the Global, Multiple Ascending Dose Phase 1/2 DELIVER Clinical Trial Anticipated in…
– Data from the Global, Multiple Ascending Dose Phase 1/2 DELIVER Clinical Trial Anticipated in…
– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination…
– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination…
POMPANO BEACH, FLORIDA., March 23, 2023 (GLOBE NEWSWIRE) — BioStem Technologies (“BioStem” or the “Company”)…
POMPANO BEACH, FLORIDA., March 23, 2023 (GLOBE NEWSWIRE) — BioStem Technologies (“BioStem” or the “Company”)…
– Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer’s disease – Received…
– Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer’s disease – Received…
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical…
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical…
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) — Psyence Group Inc (CSE:PSYG | OTCQB:…
VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) — Psyence Group Inc (CSE:PSYG | OTCQB:…
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX) (“Genelux” or…
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX) (“Genelux” or…
– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from…
– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from…
CHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a…
CHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a…